TriangleHEALTH PROFESSIONAL · SOURCE READING
Fludarabine, cytarabine, and filgrastim (FLAG)
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy
FLAG has shown antileukemic activity in patients with relapsed and refractory AML.
Evidence (FLAG):
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
Source links and citations
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
In patients with relapsed leukemia whose first remission lasted for 6 months or more, the CR rate was 81% (17 of 21 patients).
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
In patients with AML whose first remission lasted less than 6 months, or in patients with primary refractory disease, the CR rate was 30% (13 of 44 patients).[3][Level of evidence C3]
Source links and citations
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
Myelosuppression and mucositis were common therapy-related toxicities.
Idarubicin has been added to this regimen as well (FLAG-Ida).[4]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice